Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: A mono-institutional case-cohort report

Breast Journal

Volumn 18, Issue 5, 2012, Pages 470-474

  Aurilio, Gaetano ^a   Munzone, Elisabetta ^a   Botteri, Edoardo ^b   Sciandivasci, Angela ^a   Adamoli, Laura ^a   Minchella, Ida ^a   Esposito, Angela ^a   Cullurã, Daniela ^a   Curigliano, Giuseppe ^a   Colleoni, Marco ^a   Goldhirsch, Aron ^a   Nolè, Franco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Div of Epidemiol and Biostatistics   (Italy)

Author keywords

advanced breast cancer; cyclophosphamide; fulvestrant; methotrexate; metronomic chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FULVESTRANT; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL PAIN; HUMAN; HUMAN TISSUE; MEDICAL RECORD REVIEW; METRONOMIC DRUG ADMINISTRATION; NAUSEA AND VOMITING; POSTMENOPAUSE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 84866078348     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2012.01278.x     Document Type: Article

References (13)

1. Robertson JF, Erikstein B, Osborne KC, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004; 43: 529-38.
2. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: anti-tumor activity and biological effects. Ann Oncol 2006; 17: 232-8.
3. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17: 961-7.
4. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: anti-tumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80.
5. Phase II trial of capecitabine in combination with fulvestrant for postmenopausal women with hormone receptor positive metastatic breast cancer. Hoffmann-La Roche AstraZeneca. NCT00534417.
6. Phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor. National Cancer Institute. NCT00423917.
7. Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 2010 Dec; 21 (12): 2342-7.
8. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-600.
9. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-403.
10. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-95.
11. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure anti-oestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70: 204-11.
12. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739-46.
13. A randomized trial with factorial design comparing fulvestrant ± lapatinib ± aromatase inhibitor in metastatic breast cancer progressing after aromatase inhibitor therapy. Eudract N°: 2007-006031-30.